KBIO : Summary for KALOBIOS PHARMACEU COM USD0.001 - Yahoo Finance

U.S. Markets open in 3 hrs 38 mins

KaloBios Pharmaceuticals, Inc. (KBIO)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.57-0.21 (-7.55%)
At close: 3:56PM EDT
People also watch
CANFPBMDMCURSPHSAEZS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.78
Open2.80
Bid0.00 x
Ask0.00 x
Day's Range2.52 - 2.80
52 Week Range1.90 - 5.21
Volume3,588
Avg. Volume8,412
Market Cap38.49M
Beta4.15
PE Ratio (TTM)-0.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    Benznidazole on Track in Progress to IND and NDA Submissions

    Investigational new drug application on track to be submitted in May 2017 Manufacturing preparations in line to produce tablets, clinical batches produced Company anticipates filing new drug application ...

  • GlobeNewswire28 days ago

    KaloBios to Participate in Inaugural U.S. Chagas Conference

    BRISBANE, Calif., March 30, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, ...

  • GlobeNewswirelast month

    KaloBios Receives M&A Advisor 2017 Turnaround Award

    BRISBANE, Calif., March 27, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has ...